e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Healthcare utilisation and treatment of asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of reimbursement changes for fixed ICS/LABA combination treatment in Iceland
U. Bjornsdottir, J.S. Jonsson, M. Jonsson, S.T. Sigurdardottir, G. Stratelis, G. Telg, M. Turesson, S. Gizurarson (Reykjavik, Gardabaer, Iceland; Södertälje, Stockholm, Sweden)
Source:
Annual Congress 2012 - Healthcare utilisation and treatment of asthma and COPD
Session:
Healthcare utilisation and treatment of asthma and COPD
Session type:
Thematic Poster Session
Number:
1005
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
U. Bjornsdottir, J.S. Jonsson, M. Jonsson, S.T. Sigurdardottir, G. Stratelis, G. Telg, M. Turesson, S. Gizurarson (Reykjavik, Gardabaer, Iceland; Södertälje, Stockholm, Sweden). Impact of reimbursement changes for fixed ICS/LABA combination treatment in Iceland. Eur Respir J 2012; 40: Suppl. 56, 1005
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain
Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence
Year: 2021
Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use?
Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma
Year: 2007
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Efficacy of montelukast as complementary therapy to fixed association ICS/LABA in asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 126s
Year: 2004
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Analysis of the cost-effectiveness of monotherapy versus fixed dose combination treatment of asthma in Republic of Moldova
Source: Annual Congress 2013 –Asthma at the bedside
Year: 2013
Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy
Source: Eur Respir J 2005; 26: Suppl. 49, 382s
Year: 2005
Real-world effectiveness and cost-effectiveness of asthma step-up options: A UK comparison of extrafine hydrofluoroalkane-beclometasone and combination therapy
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
Benefits of adjustable
versus
fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 258s
Year: 2003
Characteristics and treatment pathways of patients with COPD receiving an inhaled corticosteroid/long-acting ß2-agonist (ICS/LABA) in the UK
Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data
Year: 2021
Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients
Source: International Congress 2019 – Inhalers: adherence and preference
Year: 2019
Effect of combined inhaled corticosteroid-formoterol therapy on short-acting beta2-agonist use in Poland: a retrospective analysis of pharmacy reports
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Source: ERJ Open Res, 7 (1) 00480-2020; 10.1183/23120541.00480-2020
Year: 2021
Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Asthma control in general practice with inhaled corticosteroids and long-acting B2-agonists administered as a fixed or free combination at stable dosage: the ALISE survey
Source: Eur Respir J 2002; 20: Suppl. 38, 397s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept